Skip to main content
SpringerLink
Log in

Induktive präoperative Chemotherapie bei peritonealen Metastasen von Tumoren des unteren GI-Trakts inkl. Appendixkarzinom

  • Chapter
Peritoneale Tumoren und Metastasen

  • 1638 Accesses

Zusammenfassung

Bei einem nicht unerheblichen Teil der Patienten mit kolorektalem Karzinom (KRK) wird die Diagnose in einem fortgeschrittenen Erkrankungsstadium gestellt. Bis zu 40 % nach einer kurativen Operation erleiden eine erneute Tumorprogression. Das Rezidiv tritt bei bis zu 40 % im Operationsfeld auf und/oder ist mit einem peritonealen Befall kombiniert. Theoretisch haben diese Patienten ein erhöhtes Risiko für ein intraperitoneales wie auch für ein systemisches Therapieversagen. Es ist deshalb zu erwarten, dass die Patienten aus einer Kombination von zytoreduktiver Operation (CRS) und HIPEC sowie systemischer Chemotherapie profitieren könnten. Die unter dem Begriff «induktive Chemotherapie» in diesem Kapitel zu verstehende Prozedur ist im Rahmen eines quasi kurativen Konzeptes bei aber manifester Peritonealkarzinose anzusiedeln. Daten zeigen, dass eine Chemotherapie bei peritonealer Metastasierung eines KRK durchaus wirksam ist. Auch die Addition der Systemtherapie zusätzlich zu CRS + HIPEC bei einem Completeness of Cytoreduction Score von 0/1 entsprechend einer kompletten makroskopischen Zytoreduktion (CC-0/1) scheint wirksam zu sein.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Adachi T, Hinoi T, Egi H, Shimomura M, Ohdan H (2015) Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery. Surg Today 45: 986–992. doi: 10.1007/s00595–014–1017-y

  • Ambrose N, MacDonald F, Young J, Thompson H, Keighley M (1989) Monoclonal antibody and cytological detection of free malignant cells in the peritoneal cavity during resection of colorectal cancer--can monoclonal antibodies do better? Eur J Surg Oncol 15: 99–102

    Google Scholar 

  • Asare EA, Compton CC, Hanna NN, et al. (2016) The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer 122: 213–221. doi: 10.1002/cncr.29744

    Article  PubMed  Google Scholar 

  • Averbach A, Jacquet P, u. Sugarbaker P (1994) Surgical technique and colorectal cancer: impaction on local recurrence and survival. Tumori 81 (3 Suppl): 65–71

    Google Scholar 

  • Bachleitner-Hofmann T, Zitt M, Jäger T, et al. (ACO-ASSO), f. d. A. P. M. d. Ö. G. f. C. O. (2013) Leitlinie zur Behandlung von Patienten mit peritonealen Neoplasmen mittels zytoreduktiver Chirurgie und hyperthermer intraperitonealer Chemotherapie in Österreich. www.aco-asso.at/arbeitsgruppen/ag-peritoneale-malignome/leitlinie-zur-behandlung-von-patienten-mit-peritonealen-neoplasmen-mittels-zytoreduktiver-chirurgie-und-hyperthermer-intraperitonealer-chemotherapie-in-oesterreich/

  • Deutsche Gesellschaft für Viszeralchirurgie, Arbeitsgemeinschaft Chirurgische Onkologie (Hrsg) Basisprotokoll für ein multimodales chirurgisches Therapiekonzept zur Behandlung von Patienten mit Peritonealcarcinose mittels Peritonektomie/Multiviszeralresektion und hyperthermer intraperitonealer Chemotherapie. www.barmherzige-regensburg.de/fileadmin/user_upload/kh_regensburg/Kliniken/Allg_Visz_Chir/Peritoneal/Leistungen_Behandlungsprotokoll_Peritonealkarzinose.pdf

  • Bradley RF, Stewart JH t., Russell GB, et al. (2006) Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 30: 551–559. doi: 10.1097/01.pas.0000202039. 74837.7d

  • Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH (2003) Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer and Metastasis Reviews 22: 465–472

    Article  PubMed  Google Scholar 

  • Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC (1989) Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63: 364–367

    Article  CAS  PubMed  Google Scholar 

  • Chua TC, Moran, BJ, Sugarbaker PH, et al. (2012) Early-and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30: 2449–2456. doi: 10.1200/jco.2011.39.7166

    Article  PubMed  Google Scholar 

  • Cremolini C, Loupakis F, Antoniotti C, et al. (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16: 1306–1315. doi: 10.1016/s1470–2045(15)00122–9

  • Deraco M, Kusamura S, Laterza B, et al. (2006) Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. In Vivo 20: 773–776

    Google Scholar 

  • Devilee RA, Simkens GA, van Oudheusden TR, et al. (2016) Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 23: 2841–2848. doi: 10.1245/s10434–016–5214–3

  • Eggermont A, Steller EP, Sugarbaker PH (1987) Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 102: 71–78

    Google Scholar 

  • Elias D, Lefevre JH, Chevalier J, et al. (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27: 681–685. doi: 10.1200/jco.2008.19.7160

    Article  PubMed  Google Scholar 

  • Elias D, Gilly F, Boutitie F, et al. (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28: 63–68 doi: 10.1200/jco.2009.23.9285

    Article  PubMed  Google Scholar 

  • Franko J, Shi Q, Goldman CD, et al. (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30: 263–267. doi: 10.1200/jco.2011.37.1039

    Article  PubMed  Google Scholar 

  • Galandiuk S, Wieand H, Moertel C, et al. (1992) Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surgery, Gynecology Obstetrics 174: 27–32

    Google Scholar 

  • Glehen O, Kwiatkowski F, Sugarbaker PH, et al. (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22: 3284–3292. doi: 10.1200/jco.2004.10.012

    Article  CAS  PubMed  Google Scholar 

  • Glockzin G, Gerken M, Lang SA, et al. (2014) Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis. BMC Cancer 14: 807. doi: 10.1186/1471–2407–14–807

  • Glockzin G, Schlitt HJ, Piso P (2016) Therapeutic options for peritoneal metastasis arising from colorectal cancer. World J Gastrointest Pharmacol Ther 7: 343–352. doi: 10.4292/wjgpt.v7.i3.343

    Article  PubMed  PubMed Central  Google Scholar 

  • Goldberg RM, Sargent DJ, Morton RF, et al. (2009) NCCTG study N9741: Leveraging learning from an NCI Cooperative Group phase III trial. Oncologist.14: 970–978

    Article  CAS  PubMed  Google Scholar 

  • Heinemann V, von Weikersthal LF, Decker T, et al. (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15: 1065–1075. doi: 10.1016/s1470–2045(14)70330–4

  • Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89: 1545–1550. doi: 10.1046/j.1365–2168.2002.02274.x

  • Kim GP, Sargent DJ, Mahoney MR et al. (2009) Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 27: 2848-2854

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kohne CH (2015) Is Progression-Free Survival the Right End Point in Trials of Patients With Clearly Resectable, Borderline Resectable, and Unresectable Liver-Limited Colorectal Cancer? J Clin Oncol 33: 2406–2407. doi: 10.1200/jco.2014.60.7044

    Article  PubMed  Google Scholar 

  • Kuijpers AM, Mehta AM, Boot H, et al. (2014) Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Oncol 25: 864–869. doi: 10.1093/annonc/mdu031

    Article  CAS  PubMed  Google Scholar 

  • Lee DH, Oh SY, Lee YR, et al. (2011) A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis. Cancer Res Treat 43: 225–230. doi: 10.4143/crt.2011.43.4.225

    Article  PubMed  PubMed Central  Google Scholar 

  • Maillet M, Glehen O, Lambert J, et al. (2016) Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study. Ann Surg Oncol 23: 863–869. doi: 10.1245/s10434–015–4914–4

  • Mitry E, Fields AL, Bleiberg H, et al. (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26: 4906–4911

    Article  CAS  PubMed  Google Scholar 

  • Newland RC, Chapuis PH, Smyth EJ (1987) The prognostic value of substaging colorectal carcinoma. A prospective study of 1117 cases with standardized pathology. Cancer 60: 852–857

    Article  CAS  PubMed  Google Scholar 

  • Nordlinger B, Sorbye H, Glimelius B, et al. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007–1016. doi: 10.1016/s0140–6736(08)60455–9

  • Nordlinger B, Sorbye H, Glimelius B, et al. (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14: 1208–1215. doi: 10.1016/s1470–2045(13)70447–9

  • Passot G, You B, Boschetti G, et al. (2014) Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol 21: 2608–2614. doi: 10.1245/s10434–014–3647–0

  • Pomeranz AA, Garlock JH (1955) Postoperative recurrence of cancer of colon due to desquamated malignant cells. J Am Med Assoc 158: 1434–1436

    Article  CAS  PubMed  Google Scholar 

  • Pox C, Aretz S, Bischoff SC, et al. (2013) S3-guideline colorectal cancer version 1.0. Z Gastroenterol 51: 753–854. doi: 10.1055/s-0033–1350264

  • Primrose J, Falk S, Finch-Jones M, et al. (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15: 601–611. doi: 10.1016/s1470–2045(14)70105–6

  • Razenberg LG, van Gestel YR, Lemmens VE, et al. (2016) Bevacizumab in Addition to Palliative Chemotherapy for Patients With Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study. Clin Colorectal Cancer 15: e41–e46. doi: 10.1016/j.clcc.2015.12.006

    Article  PubMed  Google Scholar 

  • Ronnett BM, Yan H, Kurman RJ, Shmookler BM, et al. (2001). Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92: 85–91

    Article  CAS  PubMed  Google Scholar 

  • Russell AH, Pelton J, Reheis CE, et al. (1985) Adenocarcinoma of the colon: an autopsy study with implications for new therapeutic strategies. Cancer 56: 1446–1451

    Article  CAS  PubMed  Google Scholar 

  • Sadeghi B, Arvieux C, Glehen O, et al. (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88: 358–363

    Google Scholar 

  • Schwartzberg LS, Rivera F, Karthaus M, et al. (2014) PEAK: randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32: 2240–2247. doi: 10.1200/jco.2013.53.2473

    Article  CAS  PubMed  Google Scholar 

  • Spratt JS, Adcock RA, Sherrill W, Travathen S (1980) Hyperthermic peritoneal perfusion system in canines. Cancer Res 40: 253–255

    Google Scholar 

  • Van Cutsem E, Cervantes A, Adam R, et al. (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol mdw235

    Google Scholar 

  • Venook AP, Niedzwiecki D, Lenz HJ, et al. (2014) CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Paper presented at the ASCO Annual Meeting Proceedings

    Google Scholar 

  • Xie X, Zhou Z, Song Y, et al. (2016) The Management and Prognostic Prediction of Adenocarcinoma of Appendix. Sci Rep 6: 39027. doi: 10.1038/srep39027

  • Zeng Z, Cohen AM, Hajdu S, et al. (1992) Serosal cytologic study to determine free mesothelial penetration of intraperitoneal colon cancer. Cancer 70: 737–740

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCT-University Cancer Center Krankenhaus Nordwest Frankfurt, Institut für Klinisch Onkologische Forschung, Steinbacher Hohl 2–26, 60488, Frankfurt, Deutschland

    PD Dr. med. T. Götze & Prof. Dr. med. S.-E. Al-Batran

Authors
  1. PD Dr. med. T. Götze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. S.-E. Al-Batran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to T. Götze or S.-E. Al-Batran .

Editor information

Editors and Affiliations

  1. Charité Campus Virchow-Klinikum, Berlin, Deutschland

    Beate Rau

  2. Krankenhaus Barmherzige Brüder, Regensburg, Deutschland

    Pompiliu Piso

  3. Universitätsklinikum Tübingen, Tübingen, Deutschland

    Alfred Königsrainer

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland

About this chapter

Cite this chapter

Götze, T., Al-Batran, SE. (2018). Induktive präoperative Chemotherapie bei peritonealen Metastasen von Tumoren des unteren GI-Trakts inkl. Appendixkarzinom. In: Rau, B., Piso, P., Königsrainer, A. (eds) Peritoneale Tumoren und Metastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54500-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54500-3_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54499-0

  • Online ISBN: 978-3-662-54500-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation